 Anavexs 2-73blarcamesine produced significant reductions in cognitive decline in early Alzheimers disease as measured by ADAS-Cog and CDR-SB scores. Those who had improvements in cognition did so by an average ADAS-Cog score of 4 points, which is considered to be clinically significant. 